---
figid: PMC9627904__gr6
pmcid: PMC9627904
image_filename: gr6.jpg
figure_link: /pmc/articles/PMC9627904/figure/undfig2/
number: Central Illustration
figure_title: ''
caption: Consensus Pathway on Novel Therapy for Type 2 DiabetesSGLT2 inhibitors include
  those with proven efficacy, including empagliflozin, canagliflozin, and dapagliflozin.
  GLP-1RAs include those with proven efficacy, including liraglutide, semaglutide,
  and dulaglutide. ASCVD = atherosclerotic cardiovascular disease; eGFR = estimated
  glomerular filtration rate (mL/min/1.73 m2); GLP-1 RA = glucagon-like peptide 1
  receptor agonist; HF = heart failure; LVEF = left ventricular ejection fraction;
  PCE = Pooled Cohort Equation; RF = risk factor; SGLT2 i = sodium-glucose cotransporter
  2 inhibitor.
article_title: 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for
  Type 2 Diabetes.
citation: Chern-En Chiang, et al. JACC Asia. 2021 Sep;1(2):129-146.
year: '2021'

doi: 10.1016/j.jacasi.2021.08.003
journal_title: JACC Asia
journal_nlm_ta: JACC Asia
publisher_name: Elsevier

keywords:
- antidiabetic agents
- chronic kidney disease
- heart failure
- Taiwan Society of Cardiology
- type 2 diabetes
- ASCVD, atherosclerotic cardiovascular disease
- CKD, chronic kidney disease
- CV, cardiovascular
- eGFR, estimated glomerular filtration rate
- HF, heart failure
- GLP-1RA, glucagon-like peptide 1 receptor agonist
- MACE, major adverse cardiovascular events
- SGLT2, sodium-glucose cotransporter 2

---
